Wockhardt Q2 net loss widens to Rs 23 Crore Medical Dialogues Bureau12 Nov 2018 11:05 AM ISTIndia business stood at Rs 455 crore in the quarter as against Rs 452 crore in the same period last year. It contributed 40 per cent of the global...
USFDA completes inspection of Biocon Bengaluru plant with no observations Medical Dialogues Bureau12 Nov 2018 10:20 AM ISTZero ObservationNew Delhi: Biotechnology major Biocon has announced the US health regulator has completed the inspection of its new manufacturing...
AstraZeneca's Diabetic drug Farxiga curbs heart failure, kidney risks Medical Dialogues Bureau12 Nov 2018 9:15 AM ISTNew Delhi: The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and...
U.S. regulators snip red tape for medical devices to curb opioid crisis Medical Dialogues Bureau11 Nov 2018 10:40 AM ISTNew Delhi: Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win...
Glenmark to launch phase 1 trial in solid tumours for myeloma drug Medical Dialogues Bureau11 Nov 2018 10:20 AM ISTAn ongoing first-in-human, open-label, Phase 1 trial of GBR 1342 in multiple myeloma, is assessing the safety and tolerability of increasing doses of...
Israel's Intec Pharma eyes revenue from Parkinson's drug in 2019 Medical Dialogues Bureau11 Nov 2018 9:40 AM ISTNew Delhi: Tel Aviv, Israel's Intec Pharma, which is conducting a late-stage trial for its long-lasting pill to treat Parkinson's disease, expects to...
AstraZeneca returns to sales growth, led by cancer medicines Medical Dialogues Bureau11 Nov 2018 9:00 AM ISTLONDON: Strong demand for AstraZeneca's new drugs - especially those for cancer - drove a return to sales growth in the third quarter and the...
Fortis Q2 net loss widens to Rs 142 Crore; IHH transaction to be completed shortly Medical Dialogues Bureau10 Nov 2018 10:30 AM ISTNew Delhi: Fortis Healthcare has recently reported widening of its consolidated net loss to Rs 142 crore for the quarter ended September 2018, mainly...
Strides' subsidiary inks pact with SUDA Pharmaceuticals for migraine drug Medical Dialogues Bureau10 Nov 2018 10:00 AM ISTSumatriptan is one of the most widely used drugs for the treatment of an acute migraine in adults. SUD-001H is a first-in-class mint-flavoured oral...
Novartis division Sandoz recalls one lot of Losartan drug Medical Dialogues Bureau10 Nov 2018 9:45 AM ISTNew Delhi: Novartis has recently announced its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen...
Glenmark ties up with South Korea's SCD for ophthalmic products Medical Dialogues Bureau9 Nov 2018 10:00 AM ISTAccording to the pact, Glenmark and SCD will develop and commercialise six ophthalmic products in the US and Canada.New Delhi: Glenmark...
Lilly to consider more acquisitions like Rs 115 Crore Armo buy Medical Dialogues Bureau9 Nov 2018 9:40 AM ISTNew Delhi: Eli Lilly and Co will consider more acquisitions similar to its $1.6 billion purchase of cancer drug developer Armo Biosciences earlier...
